Low Blood Pressure News and Research

RSS

Hypotension is low blood pressure. Blood pressure is the force of blood pushing against the walls of the arteries as the heart pumps out blood. Blood pressure is measured as systolic and diastolic pressures. Systolic blood pressure is the pressure when the heart beats while pumping blood. Diastolic blood pressure is the pressure when the heart is at rest between beats. You will most often see blood pressure numbers written with the systolic number above or before the diastolic, such as 120/80 mmHg. (The mmHg is millimeters of mercury-the units used to measure blood pressure.) Normal blood pressure in adults is lower than 120/80 mmHg. Hypotension is blood pressure that's lower than 90/60 mmHg.

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the submission of a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration for VELCADE® (bortezomib) for injection to add overall survival data after a five-year follow up to the product label.

20 Jul 2011

Checklist to stay healthy and active in summer

The summer is a great season for getting in shape. Whether by playing a sport, doing an aerobic exercise routine, or just returning to that familiar running path -- this is the time for activity.

2 Jul 2011

Obama administration launches effort to tout Medicare preventive benefits

The number of Medicare recipients who take advantage of these services has only increased slightly. The availability of these benefits was expanded by the health law.

22 Jun 2011

First Edition: June 21, 2011

In today's headlines, the latest on the debt-reduction talks, the next chapter in the saga surrounding a McKinsey insurance survey and the details of the Obama administration's effort to tout the health law's prreventive care benefits.

22 Jun 2011

Acura, Pfizer receive FDA approval for OXECTA Tablets to manage severe pain

Pfizer Inc. and Acura Pharmaceuticals Inc. announce the marketing approval from the U.S. Food and Drug Administration (FDA) of OXECTATM Tablets CII.

20 Jun 2011

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced it successfully completed patient enrollment in its phase II Contrast-Induced Acute Kidney Injury study with its oral drug candidate CRMD001.

14 Jun 2011

Five guidelines for avoiding ventilators improve pediatric outcomes, reduce costs of care

Guidelines that reduce the use of mechanical ventilation with premature infants in favor of a gentler form of respiratory support can profoundly affect those children's outcomes while reducing the cost of care, according to a team of researchers at Children's Hospital Boston.

13 Jun 2011

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two studies of VELCADE (bortezomib) for Injection based combinations in patients with relapsed or refractory multiple myeloma (MM).

8 Jun 2011

Cancer vaccine shows improved response rate in patients

A vaccine for one of the most lethal cancers, advanced melanoma, has improved response rate and progression-free survival for patients when combined with the immunotherapy drug Interleukin-2, according to research led by scientists from The University of Texas MD Anderson Cancer Center and Indiana University Health Goshen Center for Cancer Care.

3 Jun 2011

Thrombolytic therapy linked to poor survival in pulmonary embolism patients with normal blood pressure

Although so-called clot-busting drugs are commonly used in the treatment of some patients with blood clots in the lungs, a new study conducted by researchers in Spain and the U.S. indicates the agents do not appear to be any more effective than traditional blood thinners for the majority of these patients.

17 May 2011

Millennium presents VELCADE Phase III trial data in multiple myeloma at IMW meeting

Millennium: The Takeda Oncology Company today reported the presentation of results of a randomized Phase III trial that investigated the effect of consolidation with single-agent VELCADE for Injection in newly diagnosed multiple myeloma patients after autologous stem cell transplant.

7 May 2011

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

Millennium: The Takeda Oncology Company today reported results from three studies in relapsed multiple myeloma. Two of the studies examined the use of VELCADE for Injection; the third study presents clinical data on MLN9708, the first investigational oral proteasome inhibitor.

6 May 2011

Study finds no significant link between religiosity and low blood pressure

Contrary to some earlier studies, a Loyola University Health System study has found that religious activity does not help protect against high blood pressure.

2 May 2011

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its interim analysis and clinical update for CRMD001.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

ACE, ARB combination therapy may increase risk of kidney failure, death

Elderly patients prescribed combination angiotensin converting enzyme inhibitors and angiotensin receptor blockers had a higher risk of kidney failure and death, according to a study published in CMAJ.

22 Mar 2011

ACS announces definitive agreement to acquire CredenceHealth

Affiliated Computer Services, Inc. (ACS), A Xerox Company, today announced a definitive agreement to acquire CredenceHealth, Inc., creating a simple way for healthcare providers to use patient information to predict and prevent complications.

21 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

New study: Circadian system may contribute to daily pattern of vasovagal syncope

Fainting, or syncope, is quite common. About 50% of people will experience fainting at some point during their lifetime. The most common type of fainting is vasovagal syncope that is caused by a sudden drop in blood pressure resulting in reduced blood flow to the brain.

8 Mar 2011

UCH installs GE's CARESCAPE Monitor B850 to enhance clinical decision making in the NICU

GE Healthcare today announced that the University of Colorado Hospital (UCH) has installed the new CARESCAPE™ Monitor B850, the company's latest advance in bedside patient monitoring, to help enhance clinical decision making in the Neonatal Intensive Care Unit (NICU). Deployed in UCH's 50-bed NICU and Neonatal OR, the CARESCAPE Monitor B850 enables access to critical patient information from any bedside monitor anywhere in the unit.

28 Feb 2011